Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Go back to Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer| (NASDAQ: NTRA) | Delayed: 391.86 -21.52 (5.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $413.38 | 52 Week High | $13.80 | |||
| Open | $408.47 | 52 Week Low | $6.52 | |||
| Day High | $416.00 | P/E | N/A | |||
| Day Low | $390.78 | EPS | $0.00 | |||
| Volume | 686,032 | |||||



